Polyneuron: Polyneuron submits clinical trial application

Polyneuron Pharamceuticals, a developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, has submitted its first clinical trial application to begin a phase I/IIa study with its lead compound for the treatment of anti-MAG neuropathy, a chronic disorder of the peripheral nervous system. In addition, the biotech startup appointed Debra Barker, M.D. as Chief Medical Officer.